surmount studies tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Surmount Press Briefing #ADA2022

If eGFR is below 60 mL/min/1.73m, creatine supplementation is generally not recommended, regardless of GLP-1 use

Meanwhile, they're losing muscle every day because their body doesn't have enough protein to maintain it

2016;7(Suppl 1):806

In the Phase 2 T2D cohort, this was offset by GLP-1/GIP-mediated insulin secretion, but close monitoring of fasting glucose during titration seems warranted

A diferencia de Semaglutida (agonista GLP-1 nico) o Tirzepatida (dual GLP-1/GIP), Retatrutida activa simultneamente tres receptores metablicos: GLP-1R (saciedad y secrecin de insulina dependiente de glucosa), GIPR (homeostasis glucmica y sealizacin adiposa), y GCGR (gasto energtico, produccin heptica de glucosa y movilizacin de sustratos)

Not just for weight loss, but for [ READ MORE ] Big thighs = lower mortality risk, especially for heart health The diet industry has trained women to resent thick thighs, but science tells a more [ READ MORE ] Common causes of brain fog You walk into a room and forget why